Trial
NCT02881567
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Biogen
Collaborators
AbbVie
Condition
Relapsing-Remitting Multiple Sclerosis (RRMS)
Intervention
Daclizumab
Why stopped
Study terminated in line with Biogen decision to withdraw Zinbryta from the market and not to pursue further studies of daclizumab in MS.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-27